摘要
目的:探究精神分裂症患者攻击行为与血浆IL-6、IL-10及血清甲状腺激素水平的关系。方法:分析本院2018年2月至2020年2月收治的118例精神分裂症患者的临床资料,按其MOAS评分分为51例有攻击行为(A组)与66例无攻击行为(B组),分别测量所有患者IL-6、IL-10及甲状腺激素水平(T3、T4、TSH)指标并进行组间对比,采用Spearman分析各项指标与精神分裂症患者出现攻击行为的相关性。结果:A组MOAS量表评分各项均高于B组(P<0.05);A组IL-6指标高于B组(P>0.05),IL-10指标低于B组(P<0.05);A组甲状腺激素(T3、T4,P>0.05;TSH,P<0.05)各项指标均高于B组;精神分裂症患者攻击行为与IL-6(r=0.309)、IL-10(r=0.523)显著相关(P<0.05);攻击行为T3(r=0.540)、T4(r=0.605,P<0.05)显著相关,与TSH(r=0.214,P>0.05)相关性不显著。结论:血浆IL-6、IL-10及血清甲状腺激素中的T3、T4指标与精神分裂症患者出现攻击行为具有显著的相关性,在今后临床中需要多关注该类指标,为患者提供更优质的诊断和预后服务。
Objective:To explore the relationship between aggressive behavior and plasma IL-6,IL-10 and serum thyroid hormone levels in patients with schizophrenia.Methods:The clinical data of 118 patients with schizophrenia admitted to our hospital from February 2018 to February 2020 were analyzed.According to their MOAS scores,they were divided into 51 cases of aggressive behavior(group A)and 66 cases of non-aggressive behavior(group B),measure the levels of IL-6,IL-10 and thyroid hormone(T3,T4,TSH)in all patients and compare them between groups.Use Spearman to analyze the correlation between each index and aggressive behavior in patients with schizophrenia.Results:The scores of the MOAS scale in group A were higher than those in group B(P<0.05);the IL-6 index of group A was higher than that of group B(P>0.05),and the IL-10 index was lower than group B(P<0.05);Thyroid hormones(T3,T4,P>0.05;TSH,P<0.05)in group A were higher than those in group B;Aggressive behavior in schizophrenia patients was correlated with IL-6(r=0.309),IL-10(r=0.523)significantly correlated(P<0.05);Aggressive behavior T3(r=0.540)and T4(r=0.605,P<0.05)are significantly correlated with TSH(r=0.214),(P>0.05).The correlation is not significant.Conclusion:Plasma IL-6,IL-10 and serum thyroid hormone T3 and T4 indicators are significantly correlated with aggressive behavior in patients with schizophrenia.In the future,more attention should be paid to these indicators in order to provide patients with better quality diagnostic and prognostic services.
作者
代景兰
何金泉
罗均
叶碧瑜
DAI Jinglan;HE Jinquan;LUO Jun(Chenzhou First People's Hospital, Hunan Binzhou 423000, China)
出处
《河北医学》
CAS
2021年第4期542-546,共5页
Hebei Medicine
基金
国家自然科学基金,(编号:81471375)。
